

AMENDMENT AND RESPONSE TO OFFICE ACTION

Amendment

In the Claims

1-32. (canceled)

33. (currently amended) A method for delivering monomeric or dimeric insulin to a patient in need thereof, comprising administering to the patient a delivery formulation for the monomeric or dimeric insulin comprising an effective amount of the insulin complexed with a diketopiperazine derivative ~~in a composition which comprises microparticles of a diketopiperazine derivative in which insulin is complexed to the diketopiperazine derivative,~~ wherein the delivery formulation is prepared by complexing the insulin with microparticles of the diketopiperazine derivative, wherein the diketopiperazine derivative has the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of fumaryl, succinyl, maleyl, and glutaryl diketopiperazine.

34. (canceled)

35. (currently amended) The method of claim 33 wherein the ~~diketopiperazine~~ X is fumaryl diketopiperazine.

36. (currently amended) The method of claim 33 wherein the ~~diketopiperazine~~ X is succinyl diketopiperazine.

37. (currently amended) The method of claim 33 wherein the ~~diketopiperazine~~ X is maleyl diketopiperazine.

38. (currently amended) The method of claim 33 wherein the ~~diketopiperazine~~ X is glutaryl diketopiperazine.

AMENDMENT AND RESPONSE TO OFFICE ACTION

39. (previously presented) The method of claim 33 wherein the composition is in a dry powder form administered to the lungs via inhalation.

40. (previously presented) The method of claim 33 wherein the patient is a Type II diabetic.

41. (previously presented) The method of claim 40 wherein the composition is administered concurrently with, or less than about 20 minutes prior to, the patient eating a meal.

42. (previously presented) The method of claim 33 wherein the composition is provided in one or more unit doses of insulin, each dose equivalent to about 6 IU of insulin.